# Treatment of Intractable Common Extensor Tendon Injury Using Mesenchymal Stem Cells (Allo-ASC)

> **NCT03449082** · PHASE2 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 30 (actual)

## Conditions studied

- Lateral Epicondylitis

## Interventions

- **BIOLOGICAL:** High concentration of Allo-ASC
- **BIOLOGICAL:** Low concentration of Allo-ASC
- **DRUG:** Fibrin glue
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT03449082
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-15
- **Primary completion:** 2019-07-16
- **Final completion:** 2021-03-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03449082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03449082, "Treatment of Intractable Common Extensor Tendon Injury Using Mesenchymal Stem Cells (Allo-ASC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03449082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*